Mandate

Vinge advised IBT on its Nasdaq Stockholm main market listing

September 10, 2018 Capital Markets and Public M&A

The shares of Infant Bacterial Therapeutics AB (publ) have been admitted to trading on the main market of Nasdaq Stockholm (Mid Cap).

 Vinge advised IBT.

The Vinge team included Erik Sjöman, Christian Lindhé and Astrid Karlsson..
 

Related

Vinge has advised Northmill Group AB in connection with the issuance of tier 2 capital bonds (T2)

Vinge has advised Northmill Group AB in connection with its successful issuance of SEK 150 million tier 2 capital bonds (T2) with a floating rate interest of 3-month STIBOR + 475 basis points.
September 11, 2026

Vinge advises IK Partners and Francks Kylindustri in connection with the acquisition of Helsingborgs Kylteknik

Vinge has advised IK Partners and its portfolio company Francks Kylindustri in connection with the acquisition of Helsingborgs Kylteknik, a company specialising in refrigeration technology and refrigeration services in southern Sweden. The acquisition strengthens Francks Kylindustri’s position in southern Sweden and broadens the group’s offering within the refrigeration industry.
September 11, 2026

Vinge advises the sellers of Berg Propulsion

Vinge has advised the sellers in connection with the sale of Berg Propulsion to Kongsberg Maritime.
September 10, 2026